Dexmedetomidine for opioid-sparing postoperative analgesia: a systematic review and meta-analysis.
Yanli Sun, Yu Yao, Ying Li...
https://pubmed.ncbi.nlm.nih.gov/41527017/Actively Recruiting
Led by Vasiliki Samartzi · Updated on 2026-09-29
90
Participants Needed
1
Research Sites
8 weeks
Total Duration
Researchers are evaluating the effects of continuous low-dose infusions of esmolol and dexmedetomidine compared to placebo on opioid use and pain relief in patients undergoing laparoscopic hysterectomy. The study aims to address postoperative pain management challenges and explore opioid-sparing strategies with these two drugs during anesthesia and after surgery. This is a randomized, double-blind, placebo-controlled trial with three groups designed to compare opioid consumption and quality of recovery. Participants receive a loading dose followed by a continuous infusion of either esmolol, dexmedetomidine, or placebo normal saline during surgery. The esmolol group receives a loading dose of 0.05 mLkg and a maintenance dose of 0.3 mLkgh, while the dexmedetomidine group receives a loading dose of 0.05 mLkg and a maintenance dose of 0.3 mLkgh. The placebo group receives equivalent volumes of normal saline. All infusions are administered intraoperatively over a 10-minute loading period followed by continuous maintenance. During the study, participants opioid use is monitored in the first 24 hours after surgery using patient-controlled analgesia PCA devices. Pain intensity, sedation levels, nausea, vomiting, and quality of recovery are assessed at various time points up to 24 hours postoperatively. Additional measures include intraoperative fentanyl and propofol consumption, heart rate and blood pressure monitoring, length of stay in the recovery unit, and total hospital stay. Safety and satisfaction from analgesia are also evaluated. Participants are involved in follow-ups during their hospital stay until discharge, approximately 4 days post-surgery.
CONDITIONS
Esmolol Versus Dexmedetomidine for Opioid-sparing in Laparoscopic Gynecological Surgery
V
Vasiliki Samartzi
K
Kassiani Theodoraki, PhD, DESA
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Vasiliki Samartzi
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - During surgery
Participants receive a loading dose followed by a continuous infusion of either esmolol, dexmedetomidine, or placebo during laparoscopic hysterectomy surgery.
Single infusion session during surgery
Duration - 24 hours post-surgery
Participants' opioid use and pain levels are monitored for 24 hours after surgery using patient-controlled analgesia and pain assessments at specific time points.
Assessments at PACU arrival, discharge, and at 6, 12, and 24 hours postoperatively
Duration - Up to 4 days
Participants are observed for recovery, including length of stay in the post-anesthesia care unit and total hospital stay until discharge.
Daily visits until discharge
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Yanli Sun, Yu Yao, Ying Li...
https://pubmed.ncbi.nlm.nih.gov/41527017/Amanda M Gelineau, Michael R King, Karim S Ladha...
https://pubmed.ncbi.nlm.nih.gov/29028742/Emidio Dias da Silva Neto, Felipe S Thyrso de Lara, Samuel Navarro Abreu...
https://pubmed.ncbi.nlm.nih.gov/41134986/Richard Watts, Venkatesan Thiruvenkatarajan, Marni Calvert...
https://pubmed.ncbi.nlm.nih.gov/28413270/Arthur Salomé, Hakim Harkouk, Dominique Fletcher...
https://pubmed.ncbi.nlm.nih.gov/34065937/Vasiliki Samartzi
Lead Sponsor